Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer

Drugs

Volumn 54, Issue 3, 1997, Pages 447-472

  Noble, Stuart ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; FLUOROURACIL; GEMCITABINE; PYRIMIDINE ANTAGONIST;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; REVIEW;

EID: 0030870485     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754030-00009     Document Type: Review

References (121)

1. Guchelaar H-J, Richel DJ, van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996 Jan; 22: 15-31
2. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′.2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993 Jan; 19: 45-55
3. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995 Dec; 6 Suppl. 6: 7-13
4. Plunkett W, Huang P, Xu Y-Z, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995 Aug; 22 Suppl. 11: 3-10
5. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996 Oct; 23 Suppl. 10: 3-15
6. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988 Jul 15; 48: 4024-31
7. Gandhi V, Huang P, Xu Y-Z., et al. Metabolism and action of 2′,2′-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol 1991; 309: 125-30.
8. Harkness RA, et al., editors. Purine and pyrimidine metabolism in man VII. Part A. New York: Plenum Press, 1991
9. Heinemann V, Xu Y-Z, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-pntentiation. Cancer Res 1992 Feb 1; 52: 533-9
10. Huang P, Chubb S, Hertel LW, et al. Action of 2′,2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991 Nov 15; 51: 6110-7
11. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995 Jul; 36: 181-8
12. Ruiz van Haperen VWT, Veerman G, Vermorken JB, et al. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Bichem Pharmacol 1993 Aug 17; 46: 762-6
13. Santini V, Bernabei PA, Gozzini A, et al. Apoptotic and anti-proloferative effects of gemcitabine and gemcitabine plus ara-c on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica 1997; 82: 11-5
14. Botiffard DY, Momparler LF, Momparler RL. Comparison of antineoplastic activity of 2′,2′-difluorodeoxycylidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs 1991 Feb; 2: 49-55
15. Ruiz van Haperen VWT, Veerman G, Noordhuis P, et al. Concentration and time dependent growth inhibition and metabolism in vitro by 2′,2′-difluoro-deoxycytidine (gemcitabine). Adv Exp Med Biol 1991; 309: 57-60.
16. Harkness RA, et al., editors. Purine and pyrimidine metabolism in man VII. Part A. New York: Plenum Press. 1991
17. Hanauske A-R, Degen D, Marshall MH, et al. Activity of 2′,2′-difluorodeoxycytidine (gemcitabine) apainst human tumor colony forming units. Anticancer Drugs 1992 Apr; 3: 143-6
18. Cory AH, Hertel LW, Kroin JS, et al. Effects of 2′,2′-difluorodeoxyeytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells. Oncol Res 1993; 5 (2): 59-63
19. Ruiz van Haperen VWT, Veerman G, Boven E, et al. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycylidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994 Oct 7; 48: 1327-39
20. Csoka K, Lilicmark J, Larsson R, et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 1995 Aug; 22 Suppl. 11: 47-53
21. neu1. Cancer Res 1996 Feb 15; 56: 794-801
22. Santini V, D'lppolito G, Bernabei PA, et al. Effects of fludarahine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement, Leuk Res 1996 Jan; 20: 37-45
23. Cronauer MV, Klocker H, Talasz, H, et al. Inhibitory effects of the nucleoside analogue geimcitabine on prostatic carcinoma cells. Prostate 1996 Mar; 28: 172-81
24. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996 Mar; 2: 521-30
25. Von Hoff DD, San Antonio Drug Development Team. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitahine. Invest New Drugs 1996; 14 (3): 265-70
26. Peters GJ, Smitskamp-Wilms E, Veerman G, et al. Three-dimensional cell cultures as a model system to evaluate the biological activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine). Nucleosides Nucleotides 1995; 14 (3-5): 661-4
27. Gruber J, Geisen E, Sgonc R, et al. 2′,2′-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Stem Cells 1996 May; 14: 351-62
28. Nakamura H, Yamaji Y, Fujita T, et al. Synergistic growth inhibition of gemcitabine/cisplatin, and gemcitabine/etoposide on a human lung cancer cell line, RERF-LC-OK [abstract]. 86th Annu Meet Am Assoc Cancer Res 1995 Mar; 36: 407
29. van Moorsel CJA, Veerman G, Bergman AM, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol 1997 Apr; 24 (2) Suppl. 7: S17-23
30. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995 Aug: 22 Suppl. 11: 72-9
31. Shewach DS, Lawrence TS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 1995 Aug; 22 Suppl. 11: 68-71
32. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996; 14(3): 257-63
33. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 1996 Oct; 23 Suppl. 10: 65-71
34. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996 Mar 1; 34: 867-72
35. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990 Jul 15; 50: 4417-22
36. Veerman G, Ruiz van Haperen VWT, Vermorken JB, et al. Antilumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodcoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996 Aug; 38: 335-42
37. Schultz RM, Merriman RL, Toth JE, et al. Evaluation of new anticancer agents against the M1A paCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 1993; 5 (6-7): 223-8
38. Merriman RL, Hertel LW, Schultz, RM, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996; 14 (3): 243-7
39. Braakhuis BJM, Ruiz van Haperen VWT, Welters MJP, et al. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer A 1995; 31A (13-14): 2335-40
40. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 1995 Aug; 22 Suppl. 11: 42-6
41. Braakhuis BJM, van Dongen GAMS, Vermorken JB, et al. Preclinical in Vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 1991 Jan 1; 51: 211-4
42. Boven E, Schipper H, Erkelens CAM, et al. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993 Jul; 68: 52-6
43. 19F-NMR-spectroscopic pharmacokinetic analysis and in vivo activity of difluorodeoxycytidine (dFdC) in two small cell lung cancer (SCLC) xenogralls. Preliminary results [abstract no. W3: 9]. Ann Oncol 1990; 1 Suppl.: 88
44. Eli Lilly and Company. Summary of product characteristics: gemcitabine. UK prescribing information. Eli Lilly, 1997
45. Abbruzzese JL, Gruncwald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991 Mar; 9: 491-8
46. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991 Jan; 27: 258-62
47. Eli Lilly and Company. Gemzar® (gemcitabine HCl) for injection. US prescribing information. Eli Lilly and Company (Indianapolis)
48. Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics of anti-metabolites. Cancer Surv 1993; 17: 123-56
49. van Moorsel CJA, Veerman G, Ruiz van Haperen VWT, et al. Differential effects of gemcitabine on nucleotide pools in 19 solid tumor cell lines. Adv Exp Biol Med. Griesmacher A, Chiba P, Muller MM, editors. Purine and pyrimidine metabolism in man IX. New York: Plenum Publishing Corporation. In press
50. Esumi Y, Mitsugi K, Seki H, et al. Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. Xenobiotica 1994 Oct; 24: 957-64
51. Abralt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994 Aug; 12: 1535-40
52. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994 Sep; 12: 1821-6
53. Begbie SD, Hui R, Levi JA, et al. Initial experience with gemcitabine for non-small cell lung cancer in Australia [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 378
54. Crinò L, Mosconi AM, Scagliotti G, et al. Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC) [abstract no. *1603]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 446a
55. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997 Jan; 15 (1): 310-6
56. Fukuoka M, Negoro S, Kudo S, et al. A late phase II study of gemcitabine (LY188011) against non-small cell lung cancer [in Japanese]. Jpn J Cancer Chemother 1996; 23 (13): 1825-32
57. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer A 1996 Feb; 32A: 243-8
58. Lund B, Ryberg M, Petersen PM, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 1994 Nov; 5: 852-3
59. Malayeri R, Ulsperger E, Baumgartner G, et al. Gemcitabine in the treatment of non-small-cell lung cancer [abstract no. 460P]. Ann Oncol 1996; 7 Suppl. 5
60. Yokoyama A, Nakai Y, Yoneda S, et al. A late phase II study of gemcitabine (LY 188011) against non-small cell lung cancer [in Japanese]. Jpn J Cancer Chemother 1996; 23 (12): 1681-8
61. Manegold C, Stahel R, Ricci S, et al. Randomized phase II study of gemcitabine (GEM) monotherapy versus cisplatin plus etoposide (C/E) in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract no. *1651]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver. Vol. 16, 460A
62. Perng R-P, Chen Y-M, Ming-Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997 May; 15 (5): 2097-102
63. Abratt RP, Bezwoda WR, Goedhals L, et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 1997 Feb; 15 (2): 744-9
64. Antón A, Artal A, Carrato A, et al. Gemcitabine plus cisplatin in advanced NSCLC: final phase II result,s [abstract no. 1656]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 461a
65. Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small cell lune cancer: a phase 11 study. J Clin Oncol 1997; 15: 297-303
66. González-Barón M, Ordonez A, Gracia M, et al. Gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC): results from a phase II study [abstract no. 1687]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 469a
67. Sandler AB, Ansari R, McClean J, et al. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 357
68. Shepherd FA, Cormier Y, Burkes R, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 1997 Jun; 24 (3) Suppl. 8: S27-30
69. Steward WP, Dunlop DJ, Cameron C, et al. Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995 Mar: 14: 351
70. Cardenal F, Rosell R, Antón A, et al. Gemcitabine + cisplatin versus etoposide + cisplatin in advanced non-small cell lung cancer patients: preliminary randomized phase III results [abstract no. *1648]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 458a
71. Eli Lilly and Company (Indianapolis), 1997. Data on file
72. Gatzemeier U, Manegold C, Eberhard W, et al. A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Semin Oncol 1997; 24 (3) Suppl. 8: S8-36-S8-38
73. Comella P, Panza N, Frasci G, et al. Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small cell lung cancer (NSCLC): a phase II randomized study [abstract no. *1615]. Thirty-Third Annual Meeting. American Society of Clinical Oncologists; 1997 May 17-20; Denver, Vol. 16, 449a
74. Copley-Merriman C, Martin C, Johnson N, et al. Economic value of gemcitabine in non-small cell lung cancer. Semin Oncol 1996 Oct; 23 Suppl. 10: 90-8
75. Copley-Merriman C, Corral J, King K, et al. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer 1996 Feb; 14: 45-61
76. Koch P, Johnson N, van Schaik J, et al. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Anticancer Drugs 1995 Dec; 6 Suppl. 6: 49-54
77. Ragnarson Tenvall G, Fernberg J-O, Grupper M, et al. Chemotherapy treatment in stage IIIB and IV NSCLC - a health economic evaluation of gemcitabine Vs standard treatment [abstract no. 467P]. Ann Oncol 1995; 7 Suppl. 5
78. Evans WK. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Semin Oncol 1996 Oct; 23 Suppl. 10: 82-9
79. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicentre randomized trial. J Clin Oncol 1988 Apr; 6 (4): 633-41
80. Palmer AJ, Brandt A. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective. Monaldi Arch Chest Dis 1996; 51 (4): 279-88
81. Will BP, Evans WK, Berthelot J-M, et al. A Canadian economic analysis of chemotherapeutic agents versus best supportive care in the treatment of advanced lung cancer [abstract]. Thirteenth Annual Meeting, International Society Technology Assessment Health Care; 1997 May 25-28; Barcelona, 77
82. Gralla RJ, Grusenmeyer PA, Brooks BJ. Evaluating the costs and cost-effectiveness of new regimens for non-small cell lung cancer (NSCLC) [abstract no. *1501]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 420a
83. Carmichael J, Fink U, Russell RCG, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996 Jan; 73: 101-5
84. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drucs 1994; 12 (1): 29-34
85. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53
86. Storniolo AM, Enas NH, Brown CA, et al. Treatment investigational new drug program for Gemzar (gemcitabine HC1) in patients with pancreas cancer (PaCa) [abstract no. 1088]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 306a
87. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997 Jun; 15 (A): 2403-13
88. Niyikiza C, Anderson JS, Tarassoff PG, et al. Prognostic factors in a randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer and in pancreatic cancer patients failing 5-FU who receive gerncitabine (GEM) as a palliative therapy [abstract no. 1624]. Thirty-Second Annual Meeting, American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, Vol. 15, 506
89. Green MR. Gemeitabine safety overview. Semin Oncol 1996 Oct: 23 Suppl. 10: 32-5
90. Tonato M, Moseoni AM, Martin C. Safety profile of gemcitabine. Anticancer Drugs 1995 Dec; 6 Suppl. 6: 27-32
91. Martin C, Pollera CF. Gemeitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res 1996: 16 (1): 9-18
92. Martin C, Lund B, Anderson H, et al. Gemeitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 1996 May; 7: 351-7
93. Eli Lilly and Company. Gemzar labelling outside the United States. Eli Lilly and Company, 1997. Data on file
94. American Cancer Society. Lung cancer. In: Cancer Facts and Figures - 1997 [online]. American Cancer Society; 1997. Available from: URL: http://www.cuncer.org/97lung.html [Accessed 1997 Mar 24]
95. Kelly P, Clancy L. Is the use of chemotherapy justified in non-small-cell lung cancer? Drugs Aging 1994 Jan; 4: 1-8
96. Carbone DP, Minna JD. Chemotherapy for non-small cell lung cancer: a meta-analysis suggests that the benefits are small. BMJ 1995 Oct 7: 311: 889-90
97. Abang AM. Chemotherapy versus best supportive care for advanced non-small-cell lung cancer. Am J Health System Pharm 1996 Dec 15; 53: 2980-4
98. Thatcher N, Niven RM, Anderson H. Aggressive vs nonaggressive therapy for metastatic NSCLC Chest 1993 May; 109 Suppl.: 87S-92S
99. Raby B, Pater J, Mackillop W. A survey of Canadian physician's beliefs about the use of radiation and chemotherapy in non-small cell lung cancer [abstract no. *1079]. 30th Annual Meeting. American Society of Clinical Oncology: 1994 May 14-17; Vol. 13, 327
100. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909
101. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer, a meta-analysis. Lancet 1993 July 3; 342: 19-21
102. Thatcher N, Anderson H, Betticher DC, et al. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs 1995 Dec: 6 Suppl. 6: 39-48
103. Hansen HH, Sørensen JB. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review. Semin Oncol 1997 Apr; 24 (2 Suppl. 7): S38-41
104. Comis RL, Friedland DM. New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Lung Cancer 1995 Jun; 12 Suppl. 2: S63-99
105. Steward WP, Dunlop DJ. New drugs in the treatment of non-small cell lung cancer. Ann Oncol 1995; 6 Suppl. 1: S49-54
106. van Zandwijk N, Giaccone G. Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 1996 Mar; 8: 120-5
107. Bergman B, Aaronson NK. Ouality-of-life and cost-effectiveness assessment in lung cancer. Curr Opin Oncol 1995; 7: 138-43
108. Riggs CE, Bennett JP. Clinical pharmacology of individual antineoplastic agents. In: Moosa AR, Schimpff SC, Robson MC, editors. Comprehensive textbook of oncology. 2nd ed. v. l. Baltimore: Williams & Wilkins, 1991: 537-64
109. The Pharmaceutical Press, editor. Martindale: the extra pharmacopeia. 30th ed. London: The Pharmaceutical Press, 1993
110. Natale RB. Overview of current and future chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 1997 Apr; 24 (2) Suppl. 7: S7-29-S7-37
111. Desch CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer patients. Curr Opin Oncol 1996 Mar; 8: 126-32
112. Thatcher N, Hopwood P, Anderson H. Improving quality ot life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer 1997; 33 Suppl. 1: S8-13
113. American Cancer Society. Pancreas Cancer. In: Cancer Facts & Figures - 1997 [online]. American Cancer Society; 1997. Available from: URL: http://www.cancer.org/97pancre.html [Accessed 1997 Mar 24]
114. Schnall SF, Macdonald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996 Apr; 23: 220-8
115. National Cancer Institute. Pancreatic cancer for phsicians. In: Clinical cancer information for physicians, WWW Cancer Net [online]. National Cancer Institute, Feb 1997. Available from: URL: http://www.arc.com/cgi-bin/Cancernet.sh?eng/physician=Pancreatic_cancer_for Physicians [Accessed 1997 Feb 26]
116. Schultz RM. Future directions for the treatment of human pancreatic carcinoma. Expert Opin Invest Drug 1995 Dec; 4: 1273-9
117. Lionetto R, Pugliese V, Bruzzi P, et al. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer A 1995; 31A (6): 882-7
118. Blackstock AW, Cox AD, Tepper JE. Treatment of pancreatic cancer: current limitations, future possibilities. Oncology 1996 Mar; 10: 301-7
119. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996 Aug 1; 78 Suppl.: 654-63
120. Faggiuolo R, Raucci CA, Roncari A, et al. Phase I study of gemcitabine and continuous infusion of 5-fluorourucil in advanced pancreatic cancer [abstract no. 1023]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 288a
121. Hidalgo M, Paz-Ares L, Hitt R, et al. Phase I-II study of gemcitabine combined with continuous infusion 5-fluorouracil as first-line chemotherapy in locally advanced and metastatic pancreatic cancer [abstract no. 1030]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, Vol. 16, 290a